ALVR Allovir Inc

Price (delayed)

$0.7366

Market cap

$84.02M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.68

Enterprise value

$20.43M

AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative ...

Highlights
ALVR's EPS is up by 40% YoY and by 6% QoQ
The net income is up by 10% year-on-year
Allovir's debt has soared by 52% YoY and by 4.4% from the previous quarter
The quick ratio has declined by 49% year-on-year and by 20% since the previous quarter

Key stats

What are the main financial stats of ALVR
Market
Shares outstanding
114.06M
Market cap
$84.02M
Enterprise value
$20.43M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.43
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$169.27M
EBITDA
-$164.13M
Free cash flow
-$125.29M
Per share
EPS
-$1.68
Free cash flow per share
-$1.1
Book value per share
$1.72
Revenue per share
$0
TBVPS
$2.18
Balance sheet
Total assets
$248.31M
Total liabilities
$52.98M
Debt
$32.89M
Equity
$195.33M
Working capital
$186.95M
Liquidity
Debt to equity
0.17
Current ratio
6.65
Quick ratio
6.48
Net debt/EBITDA
0.39
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-64.2%
Return on equity
-80.2%
Return on invested capital
-122%
Return on capital employed
-78.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALVR stock price

How has the Allovir stock price performed over time
Intraday
3.17%
1 week
5.03%
1 month
4.19%
1 year
-89.09%
YTD
8.36%
QTD
8.36%

Financial performance

How have Allovir's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$177.93M
Net income
-$168.86M
Gross margin
N/A
Net margin
N/A
The net income is up by 10% year-on-year
The operating income has grown by 4.6% YoY but it has contracted by 2.3% from the previous quarter

Growth

What is Allovir's growth rate over time

Valuation

What is Allovir stock price valuation
P/E
N/A
P/B
0.43
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ALVR's EPS is up by 40% YoY and by 6% QoQ
The price to book (P/B) is 75% less than the last 4 quarters average of 1.7
The equity has declined by 23% year-on-year and by 15% since the previous quarter

Efficiency

How efficient is Allovir business performance
Allovir's return on invested capital has increased by 17% YoY but it has decreased by 4.6% QoQ
The return on assets rose by 14% year-on-year but it has declined by 6% since the previous quarter
ALVR's return on equity is up by 12% year-on-year but it is down by 8% since the previous quarter

Dividends

What is ALVR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALVR.

Financial health

How did Allovir financials performed over time
The quick ratio has declined by 49% year-on-year and by 20% since the previous quarter
The current ratio has contracted by 49% YoY and by 20% from the previous quarter
Allovir's debt is 83% less than its equity
ALVR's debt to equity has soared by 89% year-on-year and by 21% since the previous quarter
Allovir's debt has soared by 52% YoY and by 4.4% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.